News & Updates

In patients with invasive fungal disease (IFD) who have few or no treatment options, olorofim demonstrates efficacy and good tolerability, according to the results of a single-arm, open-label phase IIb study.

Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.

Updated results from the phase IIIB HARMONIE trial demonstrate sustained efficacy of the long-acting monoclonal antibody nirsevimab against respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRTI) hospitalization through day 181 post-dose.

Infants who contract an invasive bacterial infection during the first week of life have double the risk of epilepsy in childhood, according to a register-based cohort study from Denmark.

Many patients living with cancer die of infection, and early identification of those at risk is important to prevent infection-related mortality, according to a study.

First-trimester exposure to trimethoprim-sulfamethoxazole (TMP-SMX) poses a much higher risk of severe cardiac malformation and cleft lip and palate, among others, when compared with exposure to beta-lactam antibiotics during the same period, according to a study.

Effective antiviral therapy is crucial for achieving sustained viral clearance and improving outcomes in patients with COVID-19, particularly among immunocompromised individuals.

At the recent ESCMID Global 2025 in Vienna, Austria, Ruth Mokgokong, a pharmacologist at Pfizer, UK, presented findings from the EPIC-IC trial, highlighting the benefits of an extended nirmatrelvir-ritonavir regimen in severely immunocompromised patients with symptomatic COVID-19.